drugset / Trial / NCT07251712

Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet

NCT07251712

Phase 1 Recruiting 32 enrolled Galmed Pharmaceuticals Ltd
Non-randomizedCrossoverOpen-labelTreatment

Summary

Evaluate the exposure of of Aramchol from 2 different single doses of Aramchol meglumine tablet and to compare the exposure of steady state from a selected dose of Aramchol meglumine tablet.

Timeline

Start
2025-12-25
Primary completion
2026-04-15
Completion
2026-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Aramchol Other / unclassified 300 mg

Indications

No indication recorded.